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AbsTRACT
In 2012, a European initiative called Single Hub and 
Access point for paediatric Rheumatology in Europe 
(SHARE) was launched to optimise and disseminate 
diagnostic and management regimens in Europe for 
children and young adults with rheumatic diseases. 
Juvenile localised scleroderma (JLS) is a rare disease 
within the group of paediatric rheumatic diseases (PRD) 
and can lead to significant morbidity. Evidence-based 
guidelines are sparse and management is mostly based 
on physicians’ experience. This study aims to provide 
recommendations for assessment and treatment of JLS. 
Recommendations were developed by an evidence-
informed consensus process using the European League 
Against Rheumatism standard operating procedures. 
A committee was formed, mainly from Europe, and 
consisted of 15 experienced paediatric rheumatologists 
and two young fellows. Recommendations derived 
from a validated systematic literature review were 
evaluated by an online survey and subsequently 
discussed at two consensus meetings using a nominal 
group technique. Recommendations were accepted if 
≥80% agreement was reached. In total, 1 overarching 
principle, 10 recommendations on assessment and 
6 recommendations on therapy were accepted with 
≥80% agreement among experts. Topics covered include 
assessment of skin and extracutaneous involvement and 
suggested treatment pathways. The SHARE initiative 
aims to identify best practices for treatment of patients 
suffering from PRDs. Within this remit, recommendations 
for the assessment and treatment of JLS have been 
formulated by an evidence-informed consensus process 
to produce a standard of care for patients with JLS 
throughout Europe.
InTRoduCTIon
In 2012, a European project called Single Hub 
and Access point for paediatric Rheumatology in 
Europe (SHARE) was launched to optimise and 
disseminate diagnostic and management regimens 
in Europe for children and young adults with 
rheumatic diseases.1 As currently no international 
or European consensus exists with regard to the 
assessment and treatment of juvenile rheumatic 
diseases, defining clear guidelines is one of the most 
important aims of the SHARE initiative. In this 
paper, we focus on juvenile localised scleroderma 
(JLS) consensus-based recommendations.
MeTHods
An international committee of 15 experts in paedi-
atric rheumatology was established to develop 
consensus-based recommendations for JLS.2 Euro-
pean League Against Rheumatism (EULAR) stan-
dard operating procedures for developing best 
practice were used.3 Ten experts were part of the 
SHARE consortium; five other experts were asked 
to take part to the project due to their consolidate 
clinical experience in the management of JLS.
systematic literature search
The electronic databases PubMed/MEDLINE, 
Embase and Cochrane were searched in August 2013 
and subsequently in January 2015. All synonyms 
of JLS were searched in MeSH/Emtree terms, title 
and abstract. Reference tracking was performed in 
all included studies (full search strategy in online 
supplementary figure S1). Fellows (RC, FS) and 
experts (FZ, IF) selected the relevant papers for 
validity assessment (inclusion and exclusion criteria 
shown in online supplementary figure S1): 53 out 
of 1550 papers were eventually selected. All full-
text scored papers are listed in the online supple-
mentary list 1.
Validity assessment
Every relevant paper dealing with ‘diagnosis’, 
‘assessment’ and ‘therapy’ studies has been inde-
pendently assessed for methodological quality by 
two experts, who extracted data using a predefined 
scoring system.4 Disagreements were resolved by 
the opinion of a third expert. Adapted classification 
tables for assessment and therapeutic studies were 
used to determine the level of evidence and strength 
of each recommendation.5
Recommendation development
As part of the EULAR standard operating proce-
dure,3 experts assessed validity and level of evidence 
and described the main results and conclusions of 
each paper. This information was examined by two 
experts (FZ, IF) and used to formulate 18 provi-
sional recommendations. These drafted recom-
mendations were at first presented to the expert 
committee in an online survey (100% response rate) 
and subsequently revised accordingly to responses. 
The derived recommendations were then presented 
to the expert committee and discussed using a 
nominal group technique in two face-to-face 
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Table 1 Recommendations regarding diagnosis and assessment
L s
Agreement
(%)
 
overarching principle 
All children with suspected localised scleroderma should be referred to a specialised paediatric rheumatology centre. 4 D 100
1 LoSSI, which is part of LoSCAT, is a good clinical instrument to assess activity and severity in JLS lesions and is highly recommended 
in clinical practice.
3 C 90
2 LoSDI, which is part of LoSCAT, is a good clinical instrument to assess damage in JLS and is highly recommended in clinical practice. 3 C 90
3 Infrared thermography can be used to assess activity of the lesions in JLS, but skin atrophy can give false-positive results. 4 D 90
4 A specialised US imaging, using standardised assessment and colour Doppler, may be a useful tool for assessing disease activity, 
extent of JLS and response to treatment.
4 D 100
5 All patients with JLS at diagnosis and during follow-up should be carefully evaluated with a complete joint examination, including 
the temporomandibular joint.
2a C 100
6 MRI can be considered a useful tool to assess musculoskeletal involvement in JLS, especially when the lesion crosses the joint. 3 C 100
7 It is highly recommended that all patients with JLS involving face and head, with or without signs of neurological involvement, 
have an MRI of the head at the time of the diagnosis.
3 C 90
8 All patients with JLS involving face and head should undergo an orthodontic and maxillofacial evaluation at diagnosis and during 
follow-up.
2b B 90
9 Ophthalmological assessment, including screening for uveitis, is recommended at diagnosis for every patient with JLS, especially in 
those with skin lesions on the face and scalp.
2a C 100
10 Ophthalmological follow-up, including screening for uveitis, should be considered for every patient with JLS, especially in those 
with skin lesions on the face and scalp.
3 C 100
JLS, juvenile localised scleroderma; L, level of evidence; LoSCAT, Localized Scleroderma Cutaneous Assessment Tool; LoSDI, Localized Scleroderma Skin Damage Index; LoSSI, 
Localized Scleroderma Skin Severity Index; S, strength of recommendation; US, ultrasound.
Table 2 Recommendations regarding treatment
L s
Agreement
(%)
Systemic corticosteroids may be useful in the active 
inflammatory phase of JLS. At the same time as starting 
systemic corticosteroids, MTX or an alternative DMARD 
should be started.
2b C 100
All patients with active, potentially disfiguring or 
disabling forms of JLS should be treated with oral or 
subcutaneous methotrexate at 15 mg/m²/week.
1b A 100
If acceptable clinical improvement is achieved, 
methotrexate should be maintained for at least 12 
months before tapering.
3 C 100
Mycophenolate mofetil may be used to treat severe JLS 
or MTX-refractory or MTX-intolerant patients.
2a B 100
Medium-dose UVA1 phototherapy may be used to 
improve skin softness in isolated (circumscribed) 
morphoea lesions.
1b A 100
Topical imiquimod may be used to decrease skin 
thickening of circumscribed morphoea.
3 C 100
DMARD, disease-modifying antirheumatic drug; JLS, juvenile localised scleroderma; L, level 
of evidence; MTX, methotrexate; S, strength of recommendation; UVA1, ultraviolet A1.
meetings on March 2014 in Genova (Italy) and on March 2015 
in Barcelona (Spain). At both meeting, a non-voting expert (SJV) 
facilitated the process. Recommendations were accepted when 
≥80% of the experts agreed.
ResuLTs
The literature search yielded 1550 papers; after the applica-
tion of inclusion/exclusion criteria, title/abstract and full-text 
screening, 53 papers (26 for assessment and 27 for treatment) 
were selected and sent to the expert committee for validity 
assessment. Following a consensus-based methodology, the 
scleroderma working group of SHARE formulated 22 recom-
mendations for the management of JLS. In total, 1 overarching 
principle, 10 recommendations on assessment and 6 on therapy 
were accepted with ≥80% agreement among the experts. Topics 
include assessment of skin, extracutaneous involvement and 
treatment suggestions at disease onset and in refractory disease.
We briefly describe the recommendations with corresponding 
supporting literature. Tables 1 and 2 summarise the recom-
mendations for JLS, their levels of evidence, recommendation 
strength and percentage of agreement between experts. Of note, 
two recommendations derive from randomised controlled trials 
(level of evidence 1b, strength of evidence A), while three derive 
from expert opinions (level of evidence 4, strength of evidence 
D).
overarching principle
JLS includes a group of disorders whose manifestations are 
confined to the skin and subdermal tissues and, with rare excep-
tions, do not affect internal organs. The most widely used classi-
fication includes five subtypes: circumscribed morphoea, linear 
scleroderma, generalised morphoea, pansclerotic morphoea, and 
the mixed subtype where a combination of two or more of the 
previous subtypes is present.2 It is a rare condition in children as 
the incidence is 3.4 cases per million children per year, the vast 
majority represented by the linear subtype.6 The female to male 
ratio of JLS is 2.4:1, the mean age at onset is approximately 
7.3 years,7 although the disease can start as early as at birth.8 
The severity of the disease varies widely from isolated plaques to 
generalised morphoea, and to extensive linear lesions involving 
limbs, trunk and/or the face and head.9
Given the rarity of the disease, the expert group agreed that 
patients with suspected JLS should be referred to a specialised 
paediatric rheumatology centre for clinical assessment and treat-
ment (table 1).
Assessment of skin lesions
The assessment of disease activity is crucial in patients with JLS. 
At the time of diagnosis and during follow-up, it is fundamental 
to determine whether a lesion is active in order to establish an 
appropriate treatment regimen. Indeed, quantifying the activity 
of specific lesions is important in order to evaluate the response 
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to therapy. As for disease activity and severity, the experts agreed 
on using both multiparametric scoring systems and instrumental 
techniques (table 1).
LoSCAT (Localized Scleroderma Cutaneous Assessment Tool) 
is a scoring system that includes a Skin Severity Index (LoSSI) 
and a Skin Damage Index (LoSDI).10 11 LoSSI is a validated clin-
ical instrument that allows to assess activity and severity of JLS 
lesions. Indeed, it correlates well with disease activity evaluated 
by clinicians.12 LoSSI includes four domains (body surface area 
involvement, degree of erythema, skin thickness and appearance 
of new lesion or old lesion extension), each one graded from 0 
to 3, in 18 anatomic sites.10 LoSDI assesses damage by a similar 
scoring system. It includes three domains: skin atrophy, subcu-
taneous tissue loss and hypo-hyperpigmentation.11 Although this 
method does not evaluate the real size of the lesions, it can be 
performed by physicians in daily practice without the need for 
special equipment.
Infrared thermography (IT) is a non-invasive technique that 
detects infrared radiation and provides an image of the tempera-
ture distribution across the body surface.13 IT has been shown to 
be of value in the detection of active lesions with high sensitivity 
(92%) but moderate specificity (68%).13 False-positive results 
are related to the fact that old lesions lead to marked atrophy of 
skin, subcutaneous fat and muscle, with increased heat conduc-
tion from deeper tissues.
High-frequency ultrasound can detect several abnormalities 
such as increased blood flow related to inflammation as well as 
increased echogenicity due to fibrosis and loss of subcutaneous 
fat.14 15 The main limits of this tool are its operator dependency 
and the lack of standardisation.
Assessment of extracutaneous involvement
Although cutaneous and subcutaneous involvement is promi-
nent, almost 20% of patients with JLS present extracutaneous 
manifestations16 which are more frequent in patients with linear 
scleroderma and consist essentially of arthritis, neurological 
findings or other autoimmune conditions. Based on published 
data and clinical experience, the experts approved six recom-
mendations regarding the assessment and monitoring of the 
extracutaneous manifestations of JLS.
Articular involvement is the most frequent extracutaneous 
feature being present in up to 19% of patients.16 It can mani-
fest with limited range of joint motion from contractures and/
or arthritis.
Articular involvement is more common in children with the 
linear subtype, but it can be present in any subtype of JLS.16 
Therefore, all patients with JLS should be evaluated with a 
comprehensive joint examination at diagnosis and during 
follow-up. Joint symptoms are more common in patients 
with linear scleroderma and the affected joint does not always 
correlate with the site of the cutaneous lesion. Children with 
JLS who develop arthritis often have positive rheumatoid factor, 
and sometimes an elevated erythrocyte sedimentation rate.7 A 
few studies, conducted mainly in adults,17 18 reported a positive 
correlation between MRI and clinical findings of arthritis, espe-
cially during treatment. In addition to the literature evidence, 
the expert panel reported a positive experience in using this 
non-invasive tool to assess musculoskeletal involvement in JLS.
Central nervous system (CNS) involvement, although rare, 
has been reported in children with JLS, especially in those with 
linear scleroderma of the face and scalp.19 The most frequent 
signs and symptoms are seizures and headache, although 
behavioural changes and learning disabilities have been also 
described.16 20 Abnormalities on MRI, such as calcifications, 
white matter changes and vascular malformations or vascu-
litis, have also been reported.21 Considering that most of these 
changes have been reported in the linear scleroderma of the face/
head, it is mandatory to perform an MRI of the head in every 
patient with facial/scalp lesions. The lesions may occur distant 
to the skin lesions and do not apparently represent a skin down 
to deep tissue full thickness pathology. These patients should 
also be screened for ocular abnormalities16 as literature shows a 
correlation between ophthalmological and neurological involve-
ment in patients with linear forms.22 Among the ocular manifes-
tations, anterior uveitis is the most frequent one although there 
can be direct involvement of the eye, eyelid, eyelashes and orbit 
with the JLS lesions. Being usually asymptomatic, an ophthalmo-
logical screening is recommended at the time of diagnosis and 
during follow-up.
Indeed, since linear scleroderma of the face is significantly 
associated with odontostomatologic abnormalities,23 an ortho-
dontic and maxillofacial evaluation at diagnosis and during 
follow-up is recommended. Joint approaches to treatment may 
be needed, including with plastic surgery input, when there are 
severe wasting of facial fat compartments or in the linear scalp 
lesions. A comprehensive review on the most recent advances on 
monitoring and treatment of JLS has been recently published.24
Treatment
Over the years, many treatments have been tried for JLS24 
frequently without significant evidence base. Management deci-
sions should be based on the particular subtype of disease, the 
site of lesions and on the degree of activity.
Most recent reported data show effectiveness of systemic corti-
costeroids in association with methotrexate (MTX) in patients 
with active JLS, particularly in progressive linear scleroderma 
and generalised or pansclerotic morphoea. Experience with 
steroids for treatment of active disease in children is reported 
in many papers, mainly in combination with MTX.25 26 Litera-
ture evidence suggests that systemic corticosteroids are effective 
and well tolerated in the active phase of the disease and this 
was confirmed by the expert panel.27 Data from the literature 
mainly suggest two administration regimens: oral prednisone 
at a dosage of 1–2 mg/kg/day for a period of 2–3 months with 
subsequent gradual tapering,28 or pulsed high-dose intrave-
nous methylprednisolone (30 mg/kg) with various administra-
tion schedules.25 26 As far as the preferred administration route 
and dosage is concerned, no agreement has been achieved by 
the expert committee, therefore both alternatives are accepted. 
In the future, comparative trials of the two regimes could be 
considered.
As for the disease-modifying antirheumatic drugs that should 
be started in combination with corticosteroids, experts recom-
mend MTX as first-step treatment. The only randomised 
double-blind placebo-controlled trial published to date clearly 
shows the safety and efficacy of oral MTX in the treatment of 
JLS, initially in combination with corticosteroids.28 A weekly 
regimen of 15 mg/m2 MTX as single oral or subcutaneous dose is 
recommended. During the first 3 months of therapy, a course of 
corticosteroids, namely prednisone, should be used as adjunctive 
‘bridge therapy’.28 Prolonged remission off medication is more 
likely to occur in patients treated for more than 12 months after 
achieving clinical remission on medication.29 30 Therefore, once 
an acceptable clinical improvement is achieved, MTX should 
be maintained for at least 12 months before tapering, although 
longer term treatments are also frequently used.
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Figure 1 Flow chart for the treatment of newly diagnosed or 
refractory patients with juvenile localised scleroderma according to 
the clinical subtype. CS, corticosteroid; IT, infrared thermography; 
LoSCAT, Localized Scleroderma Cutaneous Assessment Tool; MMF, 
mycophenolate mofetil; MTX, methotrexate; US, ultrasound.
As for safety, several reports show that low-dose MTX is safe 
and well tolerated in the paediatric population,25–30 with a low 
rate of non-severe side effects including nausea, headache and 
transient hepatotoxicity.26 28 30
If MTX is ineffective or the disease relapses after a period 
of clinical remission (ie, cutaneous disease progression or severe 
extracutaneous manifestations) or in the case of MTX-intolerant 
patients, mycophenolate mofetil (MMF) at a dose of 500–1000 
mg/m2 may be used, despite that lack of good evidence in the 
literature.31 A retrospective study on efficacy of MMF, mostly 
in combination with MTX, in severe refractory JLS has shown 
clinical improvement in all patients and a good safety profile.31 
More trials on the safety and efficacy of MMF in a larger paedi-
atric population with localised scleroderma are needed.
Circumscribed morphoea is generally of cosmetic concern 
only and should be treated with topical treatment. Some studies 
report efficacy of imiquimod (IMQ) in decreasing the skin thick-
ening of isolated plaques of circumscribed morphoea.32 33 IMQ 
is a novel immunomodulator which is effective in the treatment 
of keloids, genital warts and basal cell skin cancers. One of its 
modes of action is to upregulate a variety of cytokines including 
interferon α and γ. These interferons are capable of inhibiting 
collagen production by fibroblasts, likely by downregulating the 
production of transforming growth factor beta.34 35 Although 
published literature includes mainly adult data in low numbers 
of patients,33 IMQ appears to be safe in the paediatric popu-
lation and despite limited evidence, the expert panel suggested 
its use in selected non-progressive or extended forms of JLS, 
although a formal trial is also recommended.
Phototherapy with ultraviolet (UV) light represents another 
possible therapeutic choice for JLS36 37 although data on its use 
in children are scarce. Medium-dose UVA1 therapy seems to 
be effective in improving skin softness and reducing skin thick-
ness with a good safety profile in adults with localised sclero-
derma.36–38 Limitations for the use of phototherapy in children 
are the need for prolonged maintenance therapy, leading to a high 
cumulative dosage of irradiation, and the increased risk of poten-
tial long-term effects such as skin ageing and carcinogenesis.39
Although there are, to date, no published trials of biologics or 
combination treatments, surveys of clinical practice demonstrate 
that tacrolimus, cyclophosphamide and a number of biologics 
(including tumour necrosis factor or interleukin-6 inhibitors) are 
being used in some patients for resistant or CNS disease.40–43 
There is also no high-level evidence regarding when to stop 
MTX or other immunosuppressive treatments. The expert panel 
suggested considering the withdrawal of MTX (or alternative 
disease-modifying drug) once the patient is in remission and off 
steroids for at least 1 year.
Based on consensus recommendations, a flow chart was 
proposed for JLS treatment (figure 1).
dIsCussIon
The scleroderma working group of SHARE formulated a total 
of 22 recommendations for the management of JLS, based on a 
systematic literature review and consensus procedure.
Topics include assessment of skin lesions and extracutaneous 
involvement, and the use of topical and systemic treatment 
options.
In total, 1 overarching principle, 10 recommendations on 
assessment and 6 on therapy were accepted with ≥80% agree-
ment among the experts.
Close monitoring of patients’ disease status and well-being by 
an experienced multidisciplinary and interdisciplinary team with 
expertise in localised scleroderma is essential for a good clinical 
outcome.
As in patients with idiopathic inflammatory myopathies or 
other rare connective tissue diseases all experts agree on the 
importance of managing JLS in specialised centres.44 As with 
all significant rare disorders, concentrating care in a few centres 
gives rise to a larger physician experience. In addition, European 
and international sharing of patients in studies provides evidence 
to improve standards of care. An important message from both 
the literature and the experience of experts is the requirement of 
a global evaluation of patients with JLS, focusing attention on the 
skin lesions and on possible extracutaneous involvement, which 
even though are rare can also be severe and potentially disabling. 
Validated scores for disease activity and damage are proposed in 
order to perform a structured assessment of outcome over time 
and to closely check their effect on the growth in children.
Recent evidence highlights the importance of treating skin 
disease aggressively as it is associated with high morbidity both 
physically and psychologically. Long-term follow-up studies are 
warranted to clarify complication risks and predictors of poor 
outcome. Given the disease rarity, international collaboration is 
crucial to recruit sufficient patients for future clinical trials with 
both current and innovative drugs.
To conclude, this SHARE initiative is based on expert opinion 
informed by the best available evidence and provides recom-
mendations for the diagnosis and treatment of patients with JLS, 
along with other paediatric rheumatic diseases, with a view to 
improving their outcome in Europe. We anticipate that these 
guidelines will likely be adopted by physicians caring for patients 
with JLS outside Europe.
It will now be important to broaden discussion and test the 
reliability of these recommendations to the wider scientific 
community and to the patients.
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